ArticleVeterinary research2025
Phosphorylation of EF-P aggravates Streptococcus suis-induced blood-brain barrier damage by enhancing serine protease production.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pathogenicity and virulence ofVirulence · 2026Review
- Phosphorylation of a novel STK substrate SstP1 links SUF Fe-S cluster biogenesis to oxidative stress resistance and virulence inVirulence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Streptococcus suis (S. suis) causes meningitis in humans and pigs. Elongation factor P (EF-P) is an important translation factor that facilitates protein synthesis with polyproline motifs. Posttranslational modification of EF-P is required for its activity and bacterial virulence. However, the regulatory mechanism of EF-P phosphorylation in S. suis-induced blood-brain barrier (BBB) disruption remains unclear. Our phosphoproteomic analysis revealed that EF-P was the key substrate of serine/threonine protein kinase (STK) in the SC19 strain. In vitro and in vivo phosphorylation assays revealed that EF-P was phosphorylated by STK at Ser-148 and Thr-176. Compared with the wild-type SC19 strain, the efp overexpression mutant strain SC19-(pSET2-EF-P) increased ZO-1 degradation in human brain endothelial cells (hCMEC/D3), the bacterial load, and the mouse survival rate; moreover, blue diffusion in the mouse brain; and brain damage, whereas the efp point mutant strain SC19-(pSET2-EF-P-T176A) abolished this enhancement effect. Furthermore, we determined that EF-P regulated the expression of the B9H01_03990 protein, which is defined as a serine protease (SP). Recombinant SP induced ZO-1 degradation in hCMEC/D3. In addition, the B9H01_03990-deficient strain (ΔB9H01_03990) alleviated ZO-1 degradation in hCMEC/D3 cells and BBB disruption in the mouse brain and transwell infection models, whereas the complementary strain CΔB9H01_03990 reversed this reduction in BBB disruption. Our study reveals that S. suis-induced BBB disruption is mediated through a novel mechanism involving EF-P phosphorylation and the proposed STK/EF-P/SP signalling axis, providing new insight into the pathogenesis of S. suis meningitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.